Cite
HARVARD Citation
Moriarty, A. et al. (n.d.). Establishment and characterization of an EGFR-mutant NSCLC XPDX model representing first-line osimertinib resistance through an acquired TRIM24-BRAF fusion. European journal of cancer. pp. S111-. [Online].